Name: Sanofi's New CEO Readies Rx Plan For Pharma Giant
Uploaded: 2019-12-06
Duration: 5 min 35 s
Description: CEO Paul Hudson meets Wall Street analysts this week to unveil his strategy to revive the French drug maker.

[ MUSIC ] Paul, you're gonna be meeting with investors soon, it's your first investor day since you took over as CEO of Sanofi three months ago, what's the key thing you wanna tell them? At this point I've been, what, close to four months in the role Feel equipped to make some accurate observations about some of the great things that I found in the company. And to point out specifically areas where I think we can accelerate, things we can do that could perhaps put us ahead and recognize Okay, so what got us here? Will it get us there? And are our priorities still valid? And how will we reflect on those, so that we can make a very good case for why we're in good investment proposition for those that'll be in the room, [ UNKNOWN ]. No doubt you will get questions about the drug portfolio, what is your strategic thinking at this point? Are you willing to let go of some products, so you can focus more of your time The products the drug that you think will be the real winners. We have to ask ourselves a little bit of a fundamental one, which is, what does it take to bring breakthrough science to patients globally? And there is a moment where you just have to be dispassionate and say, well, let's take a critical look at everything we have in our portfolio early to late stage. And is it going to change the practice of medicine? Is somebody is life going to be improved, transformed, saved by something that we have this unique to us. And if it is not unique to us, what makes us different, what makes something we have with our significant investment because it will bring something special. So you know, as somebody that comes in from the outside. I have an opportunity to have fresh eyes right across all aspects of the business. What I can tell you maybe as a sneak peek is, I'm excited by some of the things that I've seen and I'm really looking forward to To myself from John Reid who is the head of RnD, sharing a little bit of that on the tenth. Do you see any potential blockbusters in that portfilio from what you've examined so far? I've seen some things that get me excited. Can you give us any hints of what areas? No. [ LAUGH ] What I need to do with the team is take that critical look, be a little bit dispassionate And try and bring some objectivity from previous experiences of mine and theirs, and say, okay, what do we really believe here and what could we substantiate over a period of time and what will it change? I think I hope that we capture the imagination a little bit. You have said that you're interested in bringing digital technology To speed up product development. How will their drive growth. We have to accept that a lot of the data over the last few decades has been in cardboard boxes in Iron Mountain waiting in case the regulator asks as a question 10 or 20 years later about a patient group And that's how the industry was set up from when I joined. We're moving at pace to digitize that data to look for clues, to look for clues by the way in patients that have already been in studies. There's companies that specialize now in using AI to find patient populations and match them to physicians that wanna study and help them. And then match them to ours. And these are tools that didn't exist before. So I think from a drug development perspective we can pick a pace, we can be more real- time, we can look back at big data sets. And we can get medicines to market faster. So, Paul, you've been brought in that CEO to revitalize the company. In terms of strategy, is that going to involve some acquisitions? Is it going to involve spin offs at this early date in the process of what can you tell us? I tried to have the discipline to do a lot of work before starting, but to arrive at no conclusion, because it's very easy, was not easy, but it's it's I think a well trodden path. Arriving with a playbook you've used before, or a unconscious bias that you may have as for the DMA, whichever way you want to describe it, it's just simply about science. So if we go deeper into a therapeutic area, and we think the future treatment is a certain way, and we have Is Sanofi stock because it's been flat for the last five years. I mean, what is it gonna take to boost that stock and bring it alive? I think that there is a story that can be better told about the company. I think there are a lot of observers that were very clear with me. We'd like to know what the company stands for. We'd like to know where it's going. We'd like you to be clear about the value proposition it brings for all of its stakeholders, including investors. And from the 10. That's what we're going to try and do so that clarity I think will give value to the work that's already being done and done before. My arrival but I think that clarity is overdue.

Sanofi's New CEO Readies Rx Plan For Pharma Giant

Health

CEO Paul Hudson unveils revival for French drug maker.

CEO Paul Hudson meets Wall Street analysts this week to unveil his strategy to revive the French drug maker. 